Abbott Laboratories (ABT) - Forward P/E Multiple

Official company branding of Abbott Laboratories (ABT)

Innovative glucose monitoring and diagnostic systems allow Abbott Laboratories (ABT) to maintain pricing power, as evidenced by the company's forward P/E ratio chart, where the current parameter is 18.30. A broad portfolio of medical products ensures revenue independence from market volatility. Stable demand for core procedures guarantees a predictable cash flow and business resilience across any economic cycle.

ABT - Abbott Labs Projected Price to Earnings over the range 07/04/2022 - 11/12/2026

Metric breakdowns and analytics for Abbott Corp. (ABT)

- current price and projected stock value:
Stock Quotes Abbott|ABT - Analyst Forecast Prices
- market capitalization indicators:
Market Capitalization Abbott Labs|ABT - Company Buyout Price
- book capitalization information:
Book Value per Share Abbott|ABT - Company Net Assets|Market Cap to Net Assets Ratio abbott.com|ABT - Aggregate Asset Value
- debt and liquidity details:
Debt to Equity Abbott Laboratories|ABT - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Abbott Laboratories|ABT - Company Cumulative Debt|Debts to Book Capitalization Abbott Labs|ABT - Company Long-Term Indebtedness|Company Short-Term Debts Abbott|Quick Ratio abbott.com
- earnings and market ratios statistics:
ABT - Net Income|Projected Future Earnings Abbott Laboratories|ABT - P/E Multiple|Future Price to Earnings Abbott Laboratories Inc.|ABT - Price/Earnings to Growth Ratio|Enterprise Value to EBITDA Ratio Abbott Labs|ABT - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Abbott|ABT - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months abbott.com|ABT - Net earnings per share change in current year|Expected earnings per share growth for next year Abbott Laboratories
Analysis of all company metrics:Abbott
Signature product of Abbott Corp.

Forward P/E reflects the ratio of the current share price to the projected earnings for the future period. The trend of the issuer's expected P/E on the GURU.Markets platform allows for tracking valuation adjustments without waiting for quarterly reports. This metric is sensitive to changes in debt load and operational risks. For Abbott Laboratories (ABT), this ratio confirms the market's willingness to pay a premium for technological leadership. Innovative diagnostic systems ensure a stable cash cow, justifying high valuation multiples.

Who Abbott Laboratories competes with

Projected Price to Earnings TMO (Thermo Fisher)|Market Cap to Future Earnings Ratio GEHC|Forward P/E Multiple MTD (Mettler-Toledo International Inc.)|Market Cap to Projected Earnings Waters Technologies (WAT)|Bio-Techne Corporation - Forward P/E Multiple|bruker.com (BRKR) - Projected Price to Earnings|AZTA (Azenta) - Projected Price to Earnings|Varex Imaging Corp - Future Price to Earnings Multiple|Future Price to Earnings Semler Scientific Corp|Projected Price to Earnings Butterfly Corp (BFLY)|Forward P/E Multiple MLAB|QSI - Projected Price to Earnings Ratio|Forward P/E Multiple NNOX (Nano-X)|QTRX: Price to Future Earnings Ratio|908 Devices Corp - Forward P/E Multiple|Market Cap to Projected Earnings CapsoVision Inc CV|MXCT: Forward P/E Multiple|Projected Price to Earnings Rapid Micro Biosystems, Inc.|SEER (Seer) - Forward P/E Multiple|Forward P/E Multiple Hyperfine Inc|Future Price to Earnings FONAR Corp (FONR)|Future Price to Earnings DXR (daxor.com)|Spectral AI - Projected Price to Earnings|Future Price to Earnings Multiple VIVS|Aclarion, Inc. - Forward P/E Multiple|Projected Price to Earnings Ratio Akoya Biosciences|ThermoGenesis Holdings Inc. (THMO) - Future Price to Earnings|Forward Price to Earnings Multiple Talis Biomedical Corporation TLIS|Projected Price to Earnings TTOO